Welcome to Justin Stindt Consultants, your dedicated market access consulting partner for comprehensive due diligence assessments. As a leading market access consultancy, we specialize in evaluating the market potential, pricing prospects, and access pathways of pharmaceuticals and medical technologies. Our agency’s goal is to ensure that when you consider an investment, partnership, or acquisition, you have clear, data-driven insights into the asset’s market access viability and potential barriers. Our Market Access Consultancy brings deep expertise in Market Access to help you make informed decisions that maximize both patient access and commercial success.
Market Access Due Diligence: De-risking Life Science Investments
In the life sciences industry, clinical success does not guarantee commercial viability. Market Access Due Diligence is the essential process of validating an asset’s pricing prospects and reimbursement pathways before an investment, licensing deal, or acquisition. Justin Stindt Consultants provides data-driven assessments to ensure your portfolio decisions are grounded in realistic market conditions.
- Payer Insights & Pricing Benchmarks: We conduct primary research with payers and HTA experts across EU5 and the US to gauge willingness-to-pay and identify access barriers.
- Validation of Commercial Forecasts: Our team pressure-tests assumptions on patient populations, uptake, and competitive differentiation to deliver a clear-eyed peak sales evaluation.
- Agile & Tailored Execution: We deliver comprehensive, product-specific due diligence reports within 1 to 3 weeks, providing the speed and rigor required for time-sensitive M&A negotiations.
Expert Insight: Early-stage “red flag” identification in reimbursement can save millions in development costs by aligning clinical evidence with future payer requirements.
Ensuring Market Access Readiness Through Due Diligence Assessments
In today’s life sciences industry, demonstrating market access readiness is a critical component of due diligence. Big pharma companies and investors place high emphasis on how prepared a product is for pricing and reimbursement, since lack of readiness can lead to significant delays, added costs, or even failure to secure reimbursement at a sustainable price. Our consultancy addresses this need by conducting thorough Market Access due diligence reviews that examine the evidence requirements, payer expectations, and potential for success of your product. We leverage our extensive international experience across all major markets , including Europe’s “EU5” (France , Germany , Italy , Spain , UK ) and the United States , to provide a comprehensive view of the global market access landscape. With experts based in the US and Europe and a broad global network of payers and clinical specialists worldwide, we ensure that region-specific reimbursement challenges and opportunities are factored into every assessment.
Validating Market Potential, Pricing, And Access Barriers
Our due diligence assessments rigorously validate the key inputs to your asset’s commercial forecast. We begin by analyzing the target product profile in the context of the competitive landscape , identifying current and future comparator therapies, the unmet needs, and the asset’s differentiation and value proposition. This allows our consultancy to estimate the market potential (e.g. eligible patient population and uptake) under realistic conditions. To determine pricing prospects, our team of consultants conducts analogue research and pricing benchmark analyses, comparing your asset to relevant analogues in our databases and case studies of similar products. We also gather payer insights through focused primary research: leveraging our network, we organize targeted interviews or advisory boards with payers and health technology assessment (HTA) experts in key markets. Even a handful of carefully selected payer interviews per target market can yield actionable insights, uncovering market-specific pricing opportunities, gauging willingness-to-pay, and identifying any red flags or access barriers early on. This streamlined yet effective approach provides a data-backed rapid assessment of the price range that payers would likely accept, aligned with the product’s value proposition and clinical data.
Crucially, we validate and pressure-test our clients’ assumptions. For example, we confirm whether the anticipated price point is substantiated by payer feedback and the product’s comparative value. We examine if additional evidence (such as outcomes data or subgroup analyses) might be required by payers, thus flagging any potential hurdles to reimbursement. Our analyses often include a high-level pricing and reimbursement scenario analysis for major markets, highlighting best-case, base-case, and worst-case outcomes for access and pricing. The end result is a clear-eyed evaluation of the asset’s peak sales potential grounded in realistic market access conditions. This insight has proven invaluable in real-world scenarios, for instance, our due diligence work for a pre-clinical stage biotech delivered a directional pricing analysis that was instrumental in discussions with investors and potential partners on the asset’s value. By providing credible, well-researched market access projections, we help de-risk business development decisions and support our clients in negotiating deals with confidence.
Due Diligence - What Sets Justin Stindt Consultants Apart?
Our consulting approach stands out for its combination of methodological rigor and real-world savvy. Unlike other firms that might apply a one-size-fits-all checklist, we do not roll out a completely standardized methodology regardless of context, instead, our market access experts tailor each due diligence assessment to the specific product, indication, and market at hand. For example, evaluating an orphan drug with no current alternatives requires a different set of questions and assumptions than assessing a new therapy in a crowded oncology field. Our consultants take great care to adapt our pricing research techniques, comparator selection, and payer questioning to fit the unique situation of your asset, ensuring that our findings are truly relevant and actionable.
Moreover, Justin Stindt Consultants brings a wealth of experience and expert networks to every project. Our consulting firm has supported countless market access projects, including pricing strategy, reimbursement submissions, and due diligence for licensing deals, across Europe and North America. We draw on insights from hundreds of past engagements and a global network of payers, key opinion leaders, and industry partners to inform our analysis. When you work with us, you benefit from a multidisciplinary team of market access specialists, health economists, and seasoned strategists who know what decision-makers (payers, HTA agencies, investors) are looking for.
Finally, we understand that due diligence projects are time-sensitive and highly confidential. Our agile project management ensures that we deliver high-quality analyses within tight deadlines (frequently 1-3 weeks), without ever compromising on rigor. All engagements are handled with the utmost confidentiality and professionalism, so you can rely on us as an independent expert voice in your internal decision-making or negotiations. Put simply, Justin Stindt Consultants is a fast-growing consulting company offering strategy and market access due diligence consultancy services to leading pharmaceutical, biotech, and medical device clients across the globe. We operate in Europe and the United States, and our broad geographic insight, especially our in-depth knowledge of European (EU5) and U.S. payer systems, positions us to deliver due diligence assessments that truly capture the asset’s worldwide market access potential.
FAQ
1. How can Market Access insights improve a Biotech’s valuation for Series A or B?
Market Access insights increase valuation by de-risking the commercial future of an asset. By providing evidence of payer willingness-to-pay and a clear reimbursement roadmap in major markets like the US and EU5, a Biotech demonstrates that its clinical innovation will successfully translate into sustainable revenue, often making the difference between a competitive term sheet and a passed deal.
2. What do Venture Capitalists (VCs) look for in a Medtech fundraising strategy?
Beyond clinical efficacy, VCs prioritize a defined path to market adoption. This includes a robust strategy for securing DRG (Diagnosis-Related Group) codes or outpatient reimbursement, a clear understanding of the competitive landscape, and “Real-World Evidence” (RWE) plans. Investors favor ventures that can quantify their value proposition for both clinicians and healthcare payers.
3. What is included in a Market Access due diligence for pharmaceutical acquisitions?
A comprehensive due diligence assessment includes:
- Comparing the asset against current and future standards of care (estimating the pricing and uptake potential through.
- Pricing Benchmarking: Analysing similar therapeutic analogues to project realistic price ranges.
- Payer Research (Optional): Direct interviews with HTA experts and payers can help identify potential access barriers and validate secondary research results.
- Peak Sales Forecasting: Pressure-testing commercial assumptions based on realistic reimbursement scenarios.
4. How long does a professional Market Access due diligence assessment take?
At Justin Stindt Consultants, we understand that M&A and licensing deals are time-sensitive. A standard high-quality due diligence assessment can typically be completed in 1 to 3 weeks, fast enough to fit any active deal or negotiation timeline, though we have previously delivered in as little as 4 days. This agile approach ensures that decision-makers have rigorous, data-driven insights into pricing and reimbursement viability without delaying critical negotiations.
5. Why should Biotech start-ups focus on reimbursement early in the development cycle?
Early focus on reimbursement ensures that clinical trial endpoints align with payer requirements, not just regulatory (FDA/EMA) standards. Addressing “evidence gaps” early prevents costly delays in market entry and ensures that the asset is positioned for maximum value during fundraising or licensing discussions.
Meet one of our Due Diligence Assessment experts
Get in touch with our expert
CLIENT TESTIMONIALS
